Pediatrix Medical Group Management

Management Kriterienprüfungen 3/4

Pediatrix Medical Group CEO ist Jim Swift , ernannt in Jan 2023, hat eine Amtszeit von 1.83 Jahren. Die jährliche Gesamtvergütung beträgt $2.24M , bestehend aus 29% Gehalt und 71% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.2% der Aktien des Unternehmens, im Wert von $2.54M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.1 Jahre bzw. 4.3 Jahre.

Wichtige Informationen

Jim Swift

Geschäftsführender

US$2.2m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts29.0%
Amtszeit als Geschäftsführer1.8yrs
Eigentum des Geschäftsführers0.2%
Durchschnittliche Amtszeit des Managements2.1yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder4.3yrs

Jüngste Management Updates

Recent updates

Pediatrix Medical Group: The Business Is Turning

Nov 18

Pediatrix Medical Group, Inc. (NYSE:MD) Shares Fly 27% But Investors Aren't Buying For Growth

Nov 06
Pediatrix Medical Group, Inc. (NYSE:MD) Shares Fly 27% But Investors Aren't Buying For Growth

Here's Why Pediatrix Medical Group (NYSE:MD) Has A Meaningful Debt Burden

Oct 19
Here's Why Pediatrix Medical Group (NYSE:MD) Has A Meaningful Debt Burden

We Like These Underlying Return On Capital Trends At Pediatrix Medical Group (NYSE:MD)

Sep 28
We Like These Underlying Return On Capital Trends At Pediatrix Medical Group (NYSE:MD)

Improved Revenues Required Before Pediatrix Medical Group, Inc. (NYSE:MD) Stock's 32% Jump Looks Justified

Aug 07
Improved Revenues Required Before Pediatrix Medical Group, Inc. (NYSE:MD) Stock's 32% Jump Looks Justified

Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?

Jun 19
Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?

Pediatrix Medical Group (NYSE:MD) Has Some Way To Go To Become A Multi-Bagger

May 10
Pediatrix Medical Group (NYSE:MD) Has Some Way To Go To Become A Multi-Bagger

Pediatrix Medical Group, Inc.'s (NYSE:MD) Price Is Right But Growth Is Lacking

Mar 29
Pediatrix Medical Group, Inc.'s (NYSE:MD) Price Is Right But Growth Is Lacking

Pediatrix Medical Group, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 100% Above Its Share Price

Jan 10
Pediatrix Medical Group, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 100% Above Its Share Price

Pediatrix Medical Group, Inc.'s (NYSE:MD) Earnings Are Not Doing Enough For Some Investors

Dec 25
Pediatrix Medical Group, Inc.'s (NYSE:MD) Earnings Are Not Doing Enough For Some Investors

Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?

Nov 14
Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?

Is It Time To Consider Buying Pediatrix Medical Group, Inc. (NYSE:MD)?

Oct 13
Is It Time To Consider Buying Pediatrix Medical Group, Inc. (NYSE:MD)?

Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?

Aug 09
Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?

Pediatrix: Unable To Deploy Capital Tied Up In Cash Conversion Cycle, Reiterate Hold

Aug 08

At US$14.21, Is Pediatrix Medical Group, Inc. (NYSE:MD) Worth Looking At Closely?

Jul 03
At US$14.21, Is Pediatrix Medical Group, Inc. (NYSE:MD) Worth Looking At Closely?

The Returns At Pediatrix Medical Group (NYSE:MD) Aren't Growing

Jun 08
The Returns At Pediatrix Medical Group (NYSE:MD) Aren't Growing

Pediatrix Medical Group (NYSE:MD) Has A Somewhat Strained Balance Sheet

Apr 26
Pediatrix Medical Group (NYSE:MD) Has A Somewhat Strained Balance Sheet

Is Now An Opportune Moment To Examine Pediatrix Medical Group, Inc. (NYSE:MD)?

Feb 20
Is Now An Opportune Moment To Examine Pediatrix Medical Group, Inc. (NYSE:MD)?

Pediatrix Medical Group Q4 2022 Earnings Preview

Feb 16

Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?

Jan 12
Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?

Pediatrix: RCM Overhang Now Too Heavy, Revise To Hold

Dec 22

Return Trends At Pediatrix Medical Group (NYSE:MD) Aren't Appealing

Dec 20
Return Trends At Pediatrix Medical Group (NYSE:MD) Aren't Appealing

Pediatrix appoints James Swift as chief executive officer

Dec 15

Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching

Nov 05
Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching

Pediatrix Medical Group GAAP EPS of $0.37 misses by $0.11, revenue of $489.92M misses by $21.54M

Nov 03

Pediatrix: These 5 Graphs Suggest It's A Buy

Sep 29

Here's Why Pediatrix Medical Group (NYSE:MD) Can Manage Its Debt Responsibly

Sep 13
Here's Why Pediatrix Medical Group (NYSE:MD) Can Manage Its Debt Responsibly

Here's What To Make Of Pediatrix Medical Group's (NYSE:MD) Decelerating Rates Of Return

Aug 29
Here's What To Make Of Pediatrix Medical Group's (NYSE:MD) Decelerating Rates Of Return

Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching

Jul 27
Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching

Pediatrix: Seeking 46% Return Objective As Speculative Buy

Jul 14

MEDNAX, Inc. (NYSE:MD) Shares Could Be 47% Below Their Intrinsic Value Estimate

Jun 24
MEDNAX, Inc. (NYSE:MD) Shares Could Be 47% Below Their Intrinsic Value Estimate

MEDNAX (NYSE:MD) Has A Pretty Healthy Balance Sheet

May 25
MEDNAX (NYSE:MD) Has A Pretty Healthy Balance Sheet

Return Trends At MEDNAX (NYSE:MD) Aren't Appealing

Apr 20
Return Trends At MEDNAX (NYSE:MD) Aren't Appealing

MEDNAX, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 96% Above Its Share Price

Mar 08
MEDNAX, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 96% Above Its Share Price

MEDNAX (NYSE:MD) Seems To Use Debt Quite Sensibly

Feb 15
MEDNAX (NYSE:MD) Seems To Use Debt Quite Sensibly

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Jim Swift im Vergleich zu den Einnahmen von Pediatrix Medical Group verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Sep 30 2024n/an/a

-US$254m

Jun 30 2024n/an/a

-US$252m

Mar 31 2024n/an/a

-US$71m

Dec 31 2023US$2mUS$650k

-US$60m

Sep 30 2023n/an/a

US$88m

Jun 30 2023n/an/a

US$95m

Mar 31 2023n/an/a

US$98m

Dec 31 2022US$1mUS$450k

US$63m

Vergütung im Vergleich zum Markt: JimDie Gesamtvergütung ($USD2.24M) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD5.50M).

Entschädigung vs. Einkommen: JimDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.


Geschäftsführer

Jim Swift (62 yo)

1.8yrs

Amtszeit

US$2,237,839

Vergütung

Dr. James D. Swift, M.D., also known as Jim, is Director of Brave Care, Inc. since October 2021. He had been the Chief Operating Officer at Pediatrix Medical Group, Inc. since May 2022 until December 31, 2...


Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
James Swift
CEO & Director1.8yrsUS$2.24m0.20%
$ 2.5m
Mary Ann Moore
Chief Administrative Officer2.1yrsUS$1.83m0.18%
$ 2.3m
Kasandra Rossi
Executive VPless than a yearkeine Daten0.052%
$ 654.6k
John Pepia
Senior VP & Chief Accounting Officer8.5yrsUS$1.43mkeine Daten
Cheryl VanPatten
Senior VP & Chief Information Officer2.8yrskeine Datenkeine Daten
Charles Lynch
Senior VP of Financeno datakeine Datenkeine Daten
Meghan Lublin
Senior VP3.3yrskeine Datenkeine Daten
Debra McRoberts
Senior Vice President of People Servicesless than a yearkeine Datenkeine Daten
Daniel Corcoran
Senior Vice President of Administration & Managed Careno datakeine Datenkeine Daten
Mike Ashford
President of Regional Operations (Central)no datakeine Datenkeine Daten
Michael Dwyer
President of Regional Operations (South-Central)no datakeine Datenkeine Daten
Nanette Sanders
Senior Vice President of Operationsno datakeine Datenkeine Daten

2.1yrs

Durchschnittliche Betriebszugehörigkeit

62yo

Durchschnittliches Alter

Erfahrenes Management: MDDas Führungsteam des Unternehmens gilt als erfahren (2.1 Jahre durchschnittliche Betriebszugehörigkeit).


Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
James Swift
CEO & Director1.7yrsUS$2.24m0.20%
$ 2.5m
Mark Ordan
Chair4.3yrsUS$554.45k0.16%
$ 2.1m
Guy Sansone
Lead Independent Director4.3yrsUS$295.00k0.081%
$ 1.0m
Thomas McEachin
Independent Director4.3yrsUS$252.50k0.065%
$ 817.5k
Sylvia Young
Independent Director1.5yrsUS$201.00k0.035%
$ 436.7k
John Starcher
Independent Director4.3yrsUS$230.00k0.065%
$ 817.4k
Shirley Weis
Independent Director4.3yrsUS$245.00k0.043%
$ 538.9k
Gavin Molinelli
Board Observer4.3yrskeine Datenkeine Daten
Michael Rucker
Independent Director5.5yrsUS$242.50k0.069%
$ 870.0k
Laura Linynsky
Independent Director2.5yrsUS$230.00k0.023%
$ 291.0k

4.3yrs

Durchschnittliche Betriebszugehörigkeit

61yo

Durchschnittliches Alter

Erfahrener Vorstand: MDDie Vorstandsmitglieder gelten als erfahren (4.3 Jahre durchschnittliche Amtszeit).